Therapeutic targeting of angiotensin II receptor type 1 to regulate androgen receptor in prostate cancer

Prostate

Volumn 72, Issue 14, 2012, Pages 1559-1572

  Takahashi, Satoru ^a   Uemura, Hiroji ^b   Seeni, Azman ^a,c   Tang, Mingxi ^a,d   Komiya, Masami ^a   Long, Ne ^a   Ishiguro, Hitoshi ^b   Kubota, Yoshinobu ^b   Shirai, Tomoyuki ^a  

^a NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^b YOKOHAMA CITY UNIVERSITY   (Japan)

^c ADVANCED MEDICAL AND DENTAL INSTITUTE   (Malaysia)

^d SOUTHWEST MEDICAL UNIVERSITY   (China)

Author keywords

androgen receptor; angiotensin II receptor type 1; intervention study; prostate cancer; transgenic rat

Indexed keywords

ANDROGEN RECEPTOR; ANGIOTENSIN RECEPTOR; CANDESARTAN; CASPASE; ESTROGEN RECEPTOR BETA; MITOGEN ACTIVATED PROTEIN KINASE P38; PLACEBO; PROSTATE SPECIFIC ANTIGEN; TELMISARTAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; ASSAY; CANCER GROWTH; CANCER MODEL; CARCINOGENESIS; CELL STRAIN LNCAP; CONTROLLED STUDY; DOWN REGULATION; DRUG MEGADOSE; ENZYME ACTIVATION; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; MICROARRAY ANALYSIS; NONHUMAN; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; RAT; TRANSGENIC RAT; UBIQUITINATION; UPREGULATION;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; APOPTOSIS; BENZIMIDAZOLES; BENZOATES; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; ESTROGEN RECEPTOR BETA; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MOLECULAR TARGETED THERAPY; NEOPLASMS, HORMONE-DEPENDENT; PROSTATIC NEOPLASMS; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; RATS, TRANSGENIC; RECEPTORS, ANDROGEN; TETRAZOLES;

EID: 84865483166     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22505     Document Type: Article

References (53)

1. Siegel R, Ward E, Brawley O, Jemal A,. Cancer statistics, 2011. The impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011; 61: 212-236.
2. Franceschi S, La Vecchia C,. Cancer epidemiology in the elderly. Crit Rev Oncol Hematol 2001; 39: 216-226.
3. Cunha GR, Donjacour AA, Cooks PS, Mee S, Bigsby RM, Higgins SJ, Sugimura Y,. The endocrinology and developmental biology of the prostate. Endocr Rev 1987; 8: 338-362.
4. Denis LJ, Griffiths K,. Endocrine treatment in prostate cancer. Semin Surg Oncol 2000; 18: 52-74. (Pubitemid 30036120)
5. Ager EI, Neo J, Christophi C,. The renin-angiotensin system and malignancy. Carcinogenesis 2008; 29: 1675-1684.
6. Hunyady L, Catt KJ,. Pleiotropic AT1 receptor signaling pathways mediating physiological and pathogenic actions of angiotensin II. Mol Endocrinol 2006; 20: 953-970.
7. Nahmias C, Strosberg D,. The angiotensin AT2 receptor: searching for signal-transduction pathways and physiological function. Trends Pharmacol Sci 1995; 16: 223-225.
8. Smith GR, Missailidis S,. Cancer, inflammation and the AT1 and AT2 receptors. J Inflamm 2004; 1: 3.
9. Uemura H, Hasumi H, Kawahara T, Sugiura S, Miyoshi Y, Nakaigawa N, Teranishi J, Noguchi K, Ishiguro H, Kubota Y,. Pilot study of angiotensin II receptor blocker in advanced hormone-refractory prostate cancer. Int J Clin Oncol 2005; 10: 405-410. (Pubitemid 41821524)
10. Yamagishi T, Uemura H, Nakaigawa N, Noguchi K, Kubota Y,. Angiotensin II blocker decreases serum prostate specific antigen in hormone refractory prostate cancer. J Urol 2005; 173: 441.
11. Uemura H, Hasumi H, Ishiguro H, Teranishi J, Miyoshi Y, Kubota Y,. Renin-angiotensin system is an important factor in hormone refractory prostate cancer. Prostate 2006; 66: 822-830.
12. Asamoto M, Hokaiwado N, Cho YM, Takahashi S, Ikeda Y, Imaida K, Shirai T,. Prostate carcinomas developing in transgenic rats with SV40 T antigen expression under probasin promoter control are strictly androgen dependent. Cancer Res 2001; 61: 4693-4700. (Pubitemid 32691878)
13. Cho YM, Takahashi S, Asamoto M, Suzuki S, Inaguma S, Hokaiwado N, Shirai T,. Age-dependent histopathological findings in the prostate of probasin/SV40 T antigen transgenic rats. Lack of influence of carcinogen or testosterone treatment. Cancer Sci 2003; 94: 153-157. (Pubitemid 36575874)
14. Seeni A, Takahashi S, Takeshita K, Tang M, Sugiura S, Sato S, Shirai T,. Suppression of prostate cancer growth by resveratrol in the transgenic rat for adenocarcinoma of prostate (TRAP) model. Asian Pacific J Cancer Prev 2008; 9: 7-14.
15. Takahashi S, Takeshita K, Seeni A, Sugiura S, Tang M, Sato S, Kuriyama H, Nakadate M, Abe K, Maeno Y, Nagao M, Shirai T,. Suppression of prostate cancer in a transgenic rat model via gamma-tocopherol activation of caspase signaling. Prostate 2009; 69: 644-651.
16. Kosaka T, Miyajima A, Takayama E, Kikuchi E, Nakashima J, Ohigashi T, Asano T, Sakamoto M, Okita H, Murai M, Hayakawa M,. Angiotensin II type I receptor antagonist as an angiogenic inhibitor in prostate cancer. Prostate 2007; 67 (1): 41-49. (Pubitemid 46013466)
17. Sporn MB,. Approaches to prevention of epithelial cancer during the preneoplastic period. Cancer Res 1976; 36: 2699-2702.
18. Parkin DM, Bray FI, Devesa SS,. Cancer burden in the year 2000. The global picture. Eur J Cancer 2001; 37 (Suppl 8): S4-S66.
19. Gronberg H,. Prostate cancer epidemiology. Lancet 2003; 361 (9360): 859-864. (Pubitemid 36331852)
20. Nelson WG, De Marzo AM, Isaacs WB,. Prostate cancer. N Engl J Med 2003; 349: 366-381. (Pubitemid 36886244)
21. Gupta S,. Prostate cancer chemoprevention: Current status and future prospects. Toxicol Appl Pharmacol 2007; 224: 369-376. (Pubitemid 47575668)
22. Nelson PS, Montgomery B,. Unconventional therapy for prostate cancer: Good, bad or questionable ? Nature Rev Cancer 2003; 3: 845-858. (Pubitemid 37376982)
23. Lippman SM, Klein EA, Goodman PJ, Lucia MS, Thompson IM, Ford LG, Parnes HL, Minasian LM, Gaziano JM, Hartline JA, Parsons JK, Bearden JD, Crawford ED, Goodman GE, Claudio J, Winquist E, Cook ED, Karp DD, Walther P, Lieber MM, Kristal AR, Darke AK, Arnold KB, Ganz PA, Santella RM, Albanes D, Taylor PR, Probstfield JL, Jagpal TJ, Crowley JJ, Meyskens FL Jr, Baker LH,., Coltman CA Jr., Effect of selenium and vitamin E on risk of prostate cancer and other cancers. JAMA 2009; 301: 39-51.
24. Thompson IM, Tangen CM, Goodman PJ, Lucia MS, Klein EA,. Chemoprevention of prostate cancer. J Urol 2009; 182: 499-507.
25. Andriole GL, Bostwick DG, Brawley OW, Gomella LG, Marberger M, Montorsi F, Pettaway CA, Tammela T, Teloken C, Tindall DJ, Somerville MC, Wilson TH, Fowler IL, Rittmaster RS, Group RS,. Effect of dutasteride on the risk of prostate cancer. N Engl J Med 2010; 362: 1192-1202.
26. Dusing R,. Effect of the angiotensin II antagonist valsartan on sexual function in hypretensive men. Blood Press Suppl 2003; 2: 29-34. (Pubitemid 38112142)
27. Nomura M, Nishii H, Ozaki Y, Fujimoto N, Matsumoto T,. An angiotensin II receptor blocker increases sexual behavior in type 2 diabetic mice. Physiol Behav 2007; 91: 223-228. (Pubitemid 46770801)
28. Yang R, Yang B, EWen Y, Fang F, Cui S, Lin G, Sun Z, Wang R, Dai Y,. Losartan, an angiotensin type I receptor, restores erectile function by downregulation of cavernous renin-angiotensin system in streptozocin-induced diabetic rats. J Sex Med 2009; 6: 696-707.
29. Cho YM, Takahashi S, Asamoto M, Suzuki S, Tang M, Shirai T,. Suppressive effects of antiandrogens, finasteride and flutamide on development of prostatic lesions in a transgenic rat model. Prostate Cancer Prostatic Dis 2007; 10: 378-383. (Pubitemid 350238088)
30. Tang M, Ogawa K, Asamoto M, Hokaiwado N, Seeni A, Suzuki S, Takahashi S, Tanaka T, Ichikawa K, Shirai T,. Protective effects of citrus nobiletin and auraptene in transgenic rats developing adenocarcinoma of the prostate (TRAP) and human prostate carcinoma cells. Cancer Sci 2007; 98: 471-477. (Pubitemid 46566174)
31. Weihua Z, Mäkelä S, Andersson LC, Salmi S, Saji S, Webster JI, Jensen EV, Nilsson S, Warner M,. Gustafsson J-Gustafsson J-Å. A role for estrogen receptor β in the regulation of growth of the ventral prostate. Proc Natl Acad Sci USA 2001; 98: 6330-6335. (Pubitemid 32492315)
32. Kato K, Takahashi S, Cui L, Toda T, Suzuki S, Futakuchi M, Sugiura S, Shirai T,. Suppressive effects of dietary genistin and daidzin on rat prostate carcinogenesis. Jpn J Cancer Res 2000; 91: 786-791.
33. Escande A, Pillon A, Servant N, Cravedi J-P, Larrea F, Muhn P, Nicolas J-C, Cavailles V, Balaguer P,. Evaluation of ligand selectivity using reporter cell lines stably expressing estrogen receptor alpha or beta. Biochem Pharmacol 2006; 71: 1459-1469.
34. Comitato R, Nesaretnam K, Leoni G, Ambra R, Canali R, Bolli A, Marino M, Virgili F,. A novel mechanism of natural vitamin E tocotrienol activity: Involvement of ERβ signal transduction. Am J Physiol Endocrinol Metab 2009; 297: E427-E437.
35. Mak P, Leav I, Pursell B, Bae D, Yang X, Taglienti CA, Gouvin LM, Sharma VM, Mercurio AM,. ERbeta impedes prostate cancer EMT by destabilizing HIF-1alpha and inhibiting VEGF-mediated snail nuclear localization: Inplications for Gleason grading. Cancer Cell 2010; 17: 319-332.
36. Kurtz TW, Pravenec M,. Antidiabetic mechanisms of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists: Beyond the renin-angiotensin system. J Hypertens 2004; 22: 2253-2261. (Pubitemid 39625096)
37. Agata J, Ura N, Yoshida H, Shinshi Y, Sasaki H, Hyakkoku M, Taniguchi S, Shimamoto K,. Olmesartan is an angiotensin II receptor blocker with an inhibitory effect on angiotensin-converting enzyme. Hypertens Res 2006; 29: 865-874. (Pubitemid 46062117)
38. Sugimoto K, Qi NR, Kazdova L, Pravenec M, Ogihara T, Kurtz TW,. Telmisartan but not valsartan increases caloric expenditure and protects against weight gain and hepatic steatosis. Hypertension 2006; 47: 1003-1009. (Pubitemid 44297575)
39. Araki K, Masaki T, Katsuragi I, Tanaka K, Kakuma T, Yoshimatsu H,. Telmisartan prevents obesity and increases the expression of uncoupling protein 1 in diet-induced obese mice. Hypertension 2006; 48: 51-57. (Pubitemid 44297524)
40. Clemenz M, Frost N, Schupp M, Caron S, Foryst-Ludwig A, Bohm C, Hartge M, Gust R, Staels B, Unger T, Kintscher U,. Liver-specific peroxisome proliferator-activated receptor alpha target gene regulation by the angiotensin type 1 receptor blocker telmisartan. Diabetes 2008; 57: 1405-1413.
41. He H, Yang D, Ma L, Luo Z, Ma S, Feng X, Cao T, Yan Z, Liu D, Tepel M, Zhu Z,. Telmisartan prevents weight gain and obesity through activation of peroxisome proliferator-activated receptor-delta-dependent pathways. Hypertension 2010; 55: 869-879.
42. Fleshner N, Fair WR, Huryk R, Heston WDW,. Vitamin E inhibit the high-fat diet promoted growth of established human prostate LNCaP tumors in nude mice. J Urol 1999; 161: 1651-1654. (Pubitemid 29420856)
43. Attar RM, Takimoto CH, Gottardis MM,. Castration-resistant prostate cancer: Locking up the molecular escape routes. Clin Cancer Res 2009; 15 (10): 3251-3255.
44. Bonkhoff H, Berges R,. From pathogenesis to prevention of castration resistant prostate cancer. Prostate 2010; 70: 100-112.
45. Chen Y, Sawyers CL, Scher HI,. Targeting the androgen receptor pathway in prostate cancer. Curr Opin Pharmacol 2008; 8: 440-448.
46. Teeter AE, Presti JCJ, Aronson WJ, Terris MK, Kane CJ, Amling CL, Freedland SJ,. Does early prostate-specific antigen doubling time (ePSADT) after radical prostatectomy, calculated using PSA values from the first detectable until the first recurrence value, correlate with standard PSADT? A report from the Shared Equal Access Regional Cancer Hospital Database Group. BJU Int 2009; 104: 1604-1609.
47. Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Dorey FJ, Walsh PC, Partin AW,. Death in patients with recurrent prostate cancer after radical prostatectomy: Prostate-specific antigen doubling time subgroups and their associated contributions to all-cause mortality. J Clin Oncol 2007; 25: 1765-1771. (Pubitemid 46797959)
48. Ponud CR, Partin AW, Eisenberger M, Chan DW, Pearson JD, Walsh PC,. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999; 281: 1591-1597. (Pubitemid 29211767)
49. Stewart AJ, Scher HI, Chen MH, McLeod DG, Carroll PR, Moul JW, D'Amico AV,. Prostate-specific antigen nadir and cancer-specific mortality following hormonal therapy for prostate-specific antigen failure. J Clin Oncol 2005; 23: 6556-6560. (Pubitemid 46190248)
50. Ward JF, Zincke H, Bergstralh EJ, Slezak JM, Blute ML,. Prostate specific antigen doubling time subsequent to radical prostatectomy as a prognosticator of outcome following salvage radiotherapy. J Urol 2004; 172: 2244-2248. (Pubitemid 39507500)
51. Ings RMJ,. Interspecies scaling and comparisons in drug development and toxicokinetics. Xenobiotica 1990; 20: 1201-1231.
52. Travis CC, White RK,. Interspecific scaling of toxicity data. Risk Anal 1988; 8: 119-125.
53. Rhomberg LR, Lewandowski TA,. Methods for identifying a default cross-species scaling factor. http://www.epagov/raf/publications/pdfs/ RHOMBERGSPAPERPDF. 2004.